64K Cellssense spotlights delivery science behind longevity products

64K Cellssense outlined the research base behind its healthy-aging strategy, including its MPNutria® nutrient delivery technology and collaboration with Clinique Eden Suisse. The company says the work is aimed at improving protection, release and bioavailability of selected ingredients as it builds anti-aging products.

Why it matters: - 64K Cellssense is trying to differentiate healthy-aging products on delivery science, not just ingredient selection. - Better protection, controlled release and bioavailability can change how effectively a nutrient performs in the body. - The company is pairing internal R&D with clinical insight from Switzerland to support product development and intellectual property.

What happened: - 64K Cellssense said on October 12, 2026, that it is presenting the research and development base behind its longevity brand. - The Swiss-rooted company said its approach combines the exclusive MPNutria® delivery technology with input from Clinique Eden Suisse. - Clinique Eden Suisse contributes insights on anti-aging needs and research priorities based on clinical experience in Switzerland.

The details: - MPNutria® is 64K Cellssense’s nutrient delivery technology. - The technology is built on more than a decade of metal-phenolic network research and dozens of peer-reviewed publications. - The research base supports protective structures tailored to different ingredients. - The company places delivery efficiency at the center of product design. - 64K Cellssense evaluates how ingredients can be protected, released and made available to the body. - The company reports improvements in absorption and bioavailability for selected nutrients in animal studies. - 64K Cellssense has also commissioned separate third-party evaluations of finished products involving human participants. - Those evaluations are meant to add product-level evidence to the development process. - A Swiss patent application filed in 2025 covers nutrient delivery associated with MPNutria®. - The patent work is part of the brand’s intellectual property strategy.

Between the lines: - The message is that delivery systems can be a moat in the crowded longevity market. - By tying product development to peer-reviewed research and third-party evaluations, 64K Cellssense is signaling a science-first positioning. - The collaboration with a Swiss clinic also helps frame the brand as clinically informed, not only commercially driven.

What's next: - 64K Cellssense appears to be continuing work that connects delivery research, product testing and patent development. - The company is using the MPNutria® platform and Swiss clinical collaboration to support future anti-aging product innovation.

The bottom line: - 64K Cellssense is betting that nutrient delivery science will be a key driver of trust and performance in longevity products.